. 2022 Sep;52(9):773-783.

doi: 10.1111/hepr.13797. Epub 2022 Jun 11.

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Takaaki Tanaka¹, Atsushi Hiraoka¹, Toshifumi Tada², Masashi Hirooka³, Kazuya Kariyama⁴, Joji Tani⁵, Masanori Atsukawa⁶, Koichi Takaguchi⁷, Ei Itobayashi⁸, Shinya Fukunishi⁹, Kunihiko Tsuji¹⁰, Toru Ishikawa¹¹, Kazuto Tajiri¹², Hironori Ochi¹³, Satoshi Yasuda¹⁴, Hidenori Toyoda¹⁴, Chikara Ogawa¹⁵, Takashi Nishimura¹⁶, Takeshi Hatanaka¹⁷, Satoru Kakizaki¹⁸, Noritomo Shimada¹⁹, Kazuhito Kawata²⁰, Atsushi Naganuma²¹, Hisashi Kosaka²², Hideko Ohama⁹, Kazuhiro Nouso⁴, Asahiro Morishita⁵, Akemi Tsutsui⁷, Takuya Nagano⁷, Norio Itokawa⁶, Tomomi Okubo⁶, Taeang Arai⁶, Michitaka Imai¹¹, Yohei Koizumi³, Shinichiro Nakamura², Kouji Joko¹³, Hiroko Iijima¹⁶, Masaki Kaibori²², Yoichi Hiasa³, Masatoshi Kudo²³, Takashi Kumada²⁴; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Affiliations

¹ Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
² Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
³ Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
⁴ Department of Hepatology, Okayama City Hospital, Okayama, Japan.
⁵ Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
⁶ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
⁷ Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
⁸ Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
⁹ Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
¹⁰ Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
¹¹ Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
¹² Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
¹³ Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
¹⁴ Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
¹⁵ Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
¹⁶ Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
¹⁷ Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan.
¹⁸ Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
¹⁹ Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
²⁰ Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
²¹ Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
²² Department of Surgery, Kansai Medical University, Hirakata, Japan.
²³ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
²⁴ Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.

PMID: 35633504
DOI: 10.1111/hepr.13797

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Takaaki Tanaka et al. Hepatol Res. 2022 Sep.

. 2022 Sep;52(9):773-783.

doi: 10.1111/hepr.13797. Epub 2022 Jun 11.

Authors

Affiliations

¹ Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
² Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
³ Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
⁴ Department of Hepatology, Okayama City Hospital, Okayama, Japan.
⁵ Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
⁶ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
⁷ Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
⁸ Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
⁹ Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
¹⁰ Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
¹¹ Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
¹² Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
¹³ Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
¹⁴ Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
¹⁵ Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
¹⁶ Department of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
¹⁷ Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan.
¹⁸ Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
¹⁹ Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
²⁰ Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
²¹ Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
²² Department of Surgery, Kansai Medical University, Hirakata, Japan.
²³ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
²⁴ Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.

PMID: 35633504
DOI: 10.1111/hepr.13797

Abstract

Background/aim: Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP-A and -B cases.

Materials/methods: From September 2020 to March 2022, 457 u-HCC patients treated with Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B = 427:30, Child-Pugh score [CPS] 5:6:7:8:9 = 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features and prognosis were retrospectively evaluated.

Results: There were no significant differences between CP-A and -B patients in regard to best response (CR:PR:SD:PD = 16:91:194:81 vs. 0:7:13:8, p = 0.739; objective response rate/disease control rate = 28.0%/78.8% vs. 25.0%/71.4%). Analysis performed using inverse probability weighting adjustments of clinical factors other than those related to hepatic reserve function with a p value < 0.10 for comparisons between patients with CP-A and -B showed that the progression-free survival (PFS) rate for CP-A cases was better (6-/12-/18-month: 58.2%/36.1%/27.8% vs. 49.6%/8.7%/non-estimable [NE], p < 0.001), as was overall survival (OS) rate (6-/12-/18-month: 89.9%/71.7%/51.4% versus 63.6%/18.4%/NE; p < 0.001). Median PFS (mPFS) and median OS (mOS) for the CPS-5 were 9.5 months/NE, and 5.1/14.0 months for the CPS-6 (both p < 0.001). Furthermore, for modified albumin-bilirubin grade (mALBI)-1/2a/2b, mPFS was 9.4/8.5/5.3 months (p < 0.001) and mOS was NE/17.8/13.4 months (p < 0.001).

Conclusion: Better hepatic function, such as mALBI grade 1 or 2a are thought to indicate a better condition for obtaining sufficient prognosis with Atez/Bev treatment for u-HCC patients, whereas for CP-B patients, who mainly shown an mALBI grade of 2b or 3, Atez/Bev might have less therapeutic efficacy.

Keywords: Child-Pugh class B; atezolizumab plus bevacizumab; hepatocellular carcinoma; modified albumin-bilirubin grade; prognosis.

PubMed Disclaimer

Cited by

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y. Tada T, et al. Cancer Med. 2023 Apr;12(7):7772-7783. doi: 10.1002/cam4.5535. Epub 2022 Dec 14. Cancer Med. 2023. PMID: 36518086 Free PMC article.
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
Piscaglia F, Masi G, Martinelli E, Cabibbo G, Di Maio M, Gasbarrini A, Iavarone M, Antonuzzo L, Mazzaferro V, Ballestrero A, Garufi C, Bergamo F, Celsa C, Marino D, Tovoli F, Ponziani FR, Pressiani T, Astolfi C, Gazzoli GC, Ciardiello F, Daniele B, Rimassa L. Piscaglia F, et al. ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27. ESMO Open. 2025. PMID: 39874903 Free PMC article. Clinical Trial.
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N. Sho T, et al. Cancers (Basel). 2022 Aug 15;14(16):3938. doi: 10.3390/cancers14163938. Cancers (Basel). 2022. PMID: 36010930 Free PMC article.
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Kinami T, Uchikawa S, Kawaoka T, Yamasaki S, Kosaka M, Johira Y, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Fujino H, Nakahara T, Ono A, Murakami E, Okamoto W, Yamauchi M, Miki D, Tsuge M, Oka S. Kinami T, et al. Cancer Med. 2024 Mar;13(5):e7025. doi: 10.1002/cam4.7025. Cancer Med. 2024. PMID: 38477514 Free PMC article.
Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor.
Ballester MP, Abril C, Merino V, Alós M, Segarra G, Tosca J, Montón C, Casasus N, Lluch P. Ballester MP, et al. Cancer Diagn Progn. 2024 Sep 1;4(5):623-630. doi: 10.21873/cdp.10373. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238615 Free PMC article.

See all "Cited by" articles

References

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6. https://doi.org/10.1002/ijc.1440
1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. https://doi.org/10.1056/nejmoa0708857
1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905. https://doi.org/10.1056/nejmoa1915745
1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73. https://doi.org/10.1016/s0140-6736(18)30207-1
1. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. https://doi.org/10.1016/s0140-6736(16)32453-9

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Affiliations

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

References

REFERENCES

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous